Evidence map›Paper›PMID 36815369›Full record

ArticleHaematologica2023

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP.

Moritz Bewarder, Dominic Kaddu-Mulindwa, Igor Age Kos, Vadim Lesan, Gerhard Held, Viola Poeschel, Lorenz Thurner, Joerg Thomas Bittenbring, Norbert Schmitz, Lorenz Truemper and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Moritz BewarderDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar. moritz.bewarder@uks.eu.
Dominic Kaddu-MulindwaDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Igor Age KosDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Vadim LesanDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Gerhard HeldDepartment of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern.
Viola PoeschelDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Lorenz ThurnerDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Joerg Thomas BittenbringDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Norbert SchmitzDepartment of Medicine A, University Hospital Muenster, Muenster.
Lorenz TruemperDepartment of Hematology and Oncology, Georg August University of Goettingen, Goettingen.
Michael PfreundschuhDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Konstantinos ChristofyllakisDepartment of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical Center, Homburg/Saar.
Markus LoefflerInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig.
Bettina AltmannInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig.
Marita ZiepertInstitute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig.
University Medical Center · USSaarland University · DELeipzig University · DEUniversity Hospital Münster · DEUniversity of Göttingen · DEWestpfalz Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinDrug TaperingHumansPrednisoneRituximabVincristineCyclophosphamideDoxorubicinPrednisoneRituximabVincristine

Identifiers

PMID36815369
PMCPMC10543194
OpenAlexW4321598860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.